caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1851319610

Jane LiesveldMD

PRACTICEGASTROINTESTINAL GROUPSee all providers at this practice →
Hematopoietic Cell Transplantation and Cellular TherapyRochester, NYI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
REFERRAL NETWORK

Where Jane Liesveld's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 11 inbound referrers · 0 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
UNIVERSITY OF ROCHESTER1613,225
CORSETTI, JAMES27157
Walter Burack
Pathology · Rochester, NY
2197
Lucy Wedow
Nurse Practitioner · Rochester, NY
17120
WANDTKE, JOHN1661
ROCHESTER GENERAL HOSPITAL1486
Alissa Huston
Hematology · Rochester, NY
1365
Paul Barr
Hematopoietic Cell Transplantation and Cellular Therapy · Rochester, NY
1348
WORMER, DUNCAN1233
James Eichelberger
Cardiology · Rochester, NY
1131
Karl Schwarz
Cardiology · Rochester, NY
1163
Refers patients to
Outbound — where patients go next
No outbound pairs above the suppression threshold.
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
309
Unique beneficiaries
—
Total services
596
Distinct HCPCS
5
Medicare payment
$39K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 16 Hematopoietic Cell Transplantation and Cellular Therapy providers in NY — top quintile (cohort median 392).
PRESCRIBING · PART D · 2024
Total Rx claims
689
Beneficiaries
—
Total drug cost
$3.7M
Distinct drugs
22
Brand share
39.2%
Top prescribed drugs
Ruxolitinib Phosphate96 claims
Acyclovir91 claims
Fluconazole58 claims
Sulfamethoxazole/Trimethoprim43 claims
Pantoprazole Sodium37 claims
QUALITY · MIPS · 2024
No data available for this provider in 2024.
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
Total received
$3K
Payment records
8
By payment type
Consulting Fee$3K
Food and Beverage$317